Orbis Diagnostics believes everyone should be empowered to understand their true health status, irrespective of who they are and where they live. High quality, accessible diagnostics enable individuals within society to make life-changing decisions with confidence.
Established in 2016, Orbis brings together a proven team of world-leading researchers, backed by New Zealand’s largest early stage deep-tech investor, Pacific Channel. Orbis has developed a ‘lab on a disk’ testing platform that uses its microfluidic platform technology to miniaturise and automate accurate lab testing for use at points of need. Originally designed for the cowshed, the first product to run on this platform was able to accurately quantify progesterone in milk for heat detection, to inform the timing of artificial insemination. With the outbreak of COVID-19, Orbis recognised how the unique features of our system could help re-enable safe travel amidst a pandemic and quickly repurposed the technology to deliver a quantitative immunity test for COVID-19.
The Orbis team are currently collaborating with the University of Otago and Christchurch Heart Institute to obtain 150 pre-COVID-19 blood samples to validate the specificity of its QIC Test relative to established medical laboratory systems.
Following this successful stage 1 testing, Orbis will seek to partner with organisations and, using the Arca Prototype, test vaccinated individuals to confirm there is a robust correlation between antibody level and vaccination status within a specific population.
Orbis' immunity screening platform is here! We're really excited about our commercial prototype - which successfully miniaturizes the highly accurate testing available in the lab onto a desktop-sized machine, readying our COVID-19 immunity test for deployment at airports.
Orbis announces an exclusive partnership with leading biometrics company IDEMIA to develop and deploy a complete immunity testing platform solution for the air travel industry that enables the best passenger experience without compromising on security. Read the announcement here.
D&K Engineering, a San Diego-based global leader in product development, offers to productise and manufacture Orbis' system.
The COVID-19 pandemic clarified the need for a scalable quantitative antibody test to verify immunity at the point of need, and Orbis’ system was perfectly suited. The team pivoted to developing a COVID-19 immunity test, exploiting the advantages of an automated system designed for a non-lab environment.
Development of a quantitative progesterone detection test of cows milk to assist with timing of insemination of cows to optimize reproduction and avoid unnecessary culling of cows with silent heats.
Proof-of-concept demonstration of a miniaturised immunoassay on our proprietary microfluidic disks, able to measure protein and fat content of cow milk.
Orbis spun out of the Photon Factory, New Zealand's internationally-recognised research lab led by Scientific Co-Founder, Professor Cather Simpson. Orbis is the second company to originate in this lab, following Engender Technologies.